



FOR IMMEDIATE RELEASE

July 1, 2026

ASOP Global Warns FDA That Bulk Compounding of GLP-1s Would Fuel Dangerous Online Market for Unapproved Weight-Loss Drugs

WASHINGTON, D.C (July 1)— The [Alliance for Safe Online Pharmacies \(ASOP Global\)](#) is urging the U.S. Food and Drug Administration (FDA) to finalize its proposal rejecting the nominations of semaglutide, tirzepatide, and liraglutide for inclusion on the agency’s 503B Bulks List, warning that allowing large-scale compounding of these drugs would further fuel a risky online marketplace for unapproved GLP-1 products.

In comments submitted to FDA, ASOP Global said there is no clinical need to compound these drugs from bulk drug substances, particularly now that FDA-approved versions are not in shortage. ASOP Global also notes that compounded GLP-1 products are increasingly being marketed and sold through online pharmacies, telehealth platforms, and social media channels where patients are often misled about what they are receiving and whether the products have been reviewed for safety and efficacy.

“Patients deserve medicines that are safe, effective, and subject to FDA’s rigorous approval standards,” said Leigh Verbois, Chair of ASOP Global’s Board of Directors. “Allowing large-scale compounding of GLP-1 products would expand an online marketplace where too many patients are being misled, exposed to weak prescribing practices, and sold products with unclear origins and unknown risks.”

ASOP Global’s comments highlight widespread consumer confusion around compounded GLP-1s. According to [the ASOP Global Foundation’s 2025 Consumer Behavior Survey](#), 77% of GLP-1 users falsely believe compounded medications are evaluated by FDA for safety and efficacy, rising to 86% among those who obtain GLP-1s through an online provider. Nearly half of GLP-1 users also incorrectly believe compounded drugs are the same as generic medicines.

The comments also point to troubling online prescribing practices. Market surveillance cited by ASOP Global found that some telehealth platforms offering compounded GLP-1s rely on questionnaires, self-reported health information, optional consultations, and identity verification systems that can reportedly be defeated using AI-generated documents. ASOP Global continues to warn that these practices can create a direct path from online advertising to unapproved compounded drugs without meaningful clinical oversight.

###

About ASOP Global

The Alliance for Safe Online Pharmacies (ASOP Global), a 501(c)(4) non-profit organization headquartered in Washington, D.C., with activities in the U.S., Canada, Europe, Latin America, and Asia, is dedicated to protecting consumers around the world, ensuring safe access to medications, and combating illegal online drug sellers. Learn more at buysaferx.pharmacy.